codenamed onx orally active secondgeneration proteasome inhibitor developed proteolix acquired onyx pharmaceuticals amgen subsidiary selectively inhibits chymotrypsinlike activity constitutive proteasome immunoproteasome investigated treatment hematologic malignancies specifically multiple myeloma phase studies ongoing february epoxyketone derivative oprozomib structurally related carfilzomib added benefit orally bioavailable like carfilzomib active bortezomibresistant multiple myeloma oprozomib granted orphan drug status treatment waldenstr√∂ms macroglobulinaemia multiple myeloma antineoplastic immunomodulatory drug article stub help wikipedia expanding httpsenwikipediaorgwikioprozomib